Summary of Study ST003493

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002142. The data can be accessed directly via it's Project DOI: 10.21228/M8R827 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003493
Study TitleCountermeasure Influence of 4-Weeks Cranberry Ingestion on Immune Dysfunction, Inflammation, and Muscle Damage Induced by Intensive Running
Study TypeThis study employed a randomized, placebo controlled, double-blind, crossover design with two 4-week supplementation periods and a 2-week washout period.
Study SummaryThis randomized crossover study used an intense 2.25-h cycling bout to induce inflammation and innate immune system perturbations in 25 cyclists who consumed 240 ml/d unsweetened cranberry or placebo beverages for 4 weeks. Unsweetened cranberry beverage intake was associated with a transient and modest post-exercise elevation in pro-inflammatory oxylipins and proteins associated with the innate immune system, but without effects on serum cortisol and muscle damage biomarkers. Additionally, cranberry beverage intake did not alter the gut microbiome composition or diversity.
Institute
Appalachian State University
DepartmentDepartment of Biology
LaboratoryHuman Performance Laboratory
Last NameNieman
First NameDavid
AddressNorth Carolina Research Campus, 600 Laureate Way, Kannapolis, NC 28081
Emailniemandc@appstate.edu
Phone(828) 773-0056
Submit Date2024-09-20
Num Groups2
Total Subjects99
Study CommentsSix blood samples were collected before and after supplementation (overnight fasted state), and at 0h-, 1.5h-, 3h-, and 24h-post-exercise. Stool and urine samples were collected pre- and post-supplementation. Outcome measures included serum creatine kinase, myoglobin, and cortisol, complete blood counts, plasma untargeted proteomics, plasma targeted oxylipins, untargeted urine metabolomics, and stool microbiome composition via whole genome shotgun (WGS) sequencing.
Raw Data AvailableYes
Raw Data File Type(s)mzML, raw(Thermo)
Analysis Type DetailLC-MS
Release Date2025-09-22
Release Version1
David Nieman David Nieman
https://dx.doi.org/10.21228/M8R827
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002142
Project DOI:doi: 10.21228/M8R827
Project Title:Countermeasure Influence of 4-Weeks Cranberry Ingestion on Immune Dysfunction, Inflammation, and Muscle Damage Induced by Intensive Running
Project Type:C18 Reversed-Phase Broad Spectrum Metabolomics
Project Summary:This study examined the effect of 4-weeks unsweetened cranberry beverage (CRAN) (309 mg polyphenols) versus placebo beverage (PLAC) ingestion (240 ml/day) in moderating exercise-induced changes in innate immunity. Participants included 25 male and female non-elite cyclists. A randomized, placebo-controlled, double-blind, crossover design was used with two 4-week supplementation periods and a 2-week washout period. Supplementation periods were followed by an intensive 2.25-h cycling bout.
Institute:Metabolomics and Exposome Laboratory at UNC Nutrition Research Institute
Department:Untargeted Analysis
Laboratory:Sumner Lab
Last Name:Rushing
First Name:Blake
Address:Nutrition Research Institute , University of North Carolina at Chapel Hill, 500 Laureate Way Kannapolis, NC 28081
Email:blake_rushing@unc.edu
Phone:704-250-5000
Funding Source:Ocean Spray (https://www.oceanspray.com/)

Subject:

Subject ID:SU003621
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Male and female
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Sample_Type Supplement Timepoint
SA384078Nieman_NIST_1Urine NIST Reference N/A N/A
SA384079Nieman_NIST_4Urine NIST Reference N/A N/A
SA384080Nieman_NIST_5Urine NIST Reference N/A N/A
SA384081Nieman_NIST_2Urine NIST Reference N/A N/A
SA384082Nieman_NIST_6Urine NIST Reference N/A N/A
SA384083Nieman_NIST_7Urine NIST Reference N/A N/A
SA384084Nieman_NIST_8Urine NIST Reference N/A N/A
SA384085Nieman_NIST_3Urine NIST Reference N/A N/A
SA384086Nieman_NIST_10Urine NIST Reference N/A N/A
SA384087Nieman_NIST_9Urine NIST Reference N/A N/A
SA384088Nieman_SP_5Urine Study Pool N/A N/A
SA384089Nieman_SP_2Urine Study Pool N/A N/A
SA384090Nieman_SP_6Urine Study Pool N/A N/A
SA384091Nieman_SP_4Urine Study Pool N/A N/A
SA384092Nieman_SP_10Urine Study Pool N/A N/A
SA384093Nieman_SP_3Urine Study Pool N/A N/A
SA384094Nieman_SP_9Urine Study Pool N/A N/A
SA384095Nieman_SP_7Urine Study Pool N/A N/A
SA384096Nieman_SP_8Urine Study Pool N/A N/A
SA384097Nieman_SP_1Urine Study Pool N/A N/A
SA384098Nieman_C_37Urine Study Cranberry T1
SA384099Nieman_C_35Urine Study Cranberry T1
SA384100Nieman_C_43Urine Study Cranberry T1
SA384101Nieman_C_47Urine Study Cranberry T1
SA384102Nieman_C_31Urine Study Cranberry T1
SA384103Nieman_C_86Urine Study Cranberry T1
SA384104Nieman_C_92Urine Study Cranberry T1
SA384105Nieman_C_53Urine Study Cranberry T1
SA384106Nieman_C_58Urine Study Cranberry T1
SA384107Nieman_C_98Urine Study Cranberry T1
SA384108Nieman_C_82Urine Study Cranberry T1
SA384109Nieman_C_62Urine Study Cranberry T1
SA384110Nieman_C_64Urine Study Cranberry T1
SA384111Nieman_C_72Urine Study Cranberry T1
SA384112Nieman_C_78Urine Study Cranberry T1
SA384113Nieman_C_88Urine Study Cranberry T1
SA384114Nieman_C_68Urine Study Cranberry T1
SA384115Nieman_C_1Urine Study Cranberry T1
SA384116Nieman_C_51Urine Study Cranberry T1
SA384117Nieman_C_5Urine Study Cranberry T1
SA384118Nieman_C_21Urine Study Cranberry T1
SA384119Nieman_C_17Urine Study Cranberry T1
SA384120Nieman_C_9Urine Study Cranberry T1
SA384121Nieman_C_15Urine Study Cranberry T1
SA384122Nieman_C_25Urine Study Cranberry T1
SA384123Nieman_C_38Urine Study Cranberry T2
SA384124Nieman_C_79Urine Study Cranberry T2
SA384125Nieman_C_18Urine Study Cranberry T2
SA384126Nieman_C_65Urine Study Cranberry T2
SA384127Nieman_C_59Urine Study Cranberry T2
SA384128Nieman_C_83Urine Study Cranberry T2
SA384129Nieman_C_32Urine Study Cranberry T2
SA384130Nieman_C_69Urine Study Cranberry T2
SA384131Nieman_C_54Urine Study Cranberry T2
SA384132Nieman_C_22Urine Study Cranberry T2
SA384133Nieman_C_52Urine Study Cranberry T2
SA384134Nieman_C_2Urine Study Cranberry T2
SA384135Nieman_C_6Urine Study Cranberry T2
SA384136Nieman_C_93Urine Study Cranberry T2
SA384137Nieman_C_16Urine Study Cranberry T2
SA384138Nieman_C_44Urine Study Cranberry T2
SA384139Nieman_C_99Urine Study Cranberry T2
SA384140Nieman_C_73Urine Study Cranberry T2
SA384141Nieman_C_48Urine Study Cranberry T2
SA384142Nieman_C_26Urine Study Cranberry T2
SA384143Nieman_C_10Urine Study Cranberry T2
SA384144Nieman_C_87Urine Study Cranberry T2
SA384145Nieman_C_36Urine Study Cranberry T2
SA384146Nieman_C_89Urine Study Cranberry T2
SA384147Nieman_C_63Urine Study Cranberry T2
SA384148Nieman_C_70Urine Study Placebo T1
SA384149Nieman_C_80Urine Study Placebo T1
SA384150Nieman_C_74Urine Study Placebo T1
SA384151Nieman_C_76Urine Study Placebo T1
SA384152Nieman_C_66Urine Study Placebo T1
SA384153Nieman_C_13Urine Study Placebo T1
SA384154Nieman_C_84Urine Study Placebo T1
SA384155Nieman_C_57Urine Study Placebo T1
SA384156Nieman_C_19Urine Study Placebo T1
SA384157Nieman_C_90Urine Study Placebo T1
SA384158Nieman_C_33Urine Study Placebo T1
SA384159Nieman_C_3Urine Study Placebo T1
SA384160Nieman_C_29Urine Study Placebo T1
SA384161Nieman_C_39Urine Study Placebo T1
SA384162Nieman_C_27Urine Study Placebo T1
SA384163Nieman_C_41Urine Study Placebo T1
SA384164Nieman_C_96Urine Study Placebo T1
SA384165Nieman_C_45Urine Study Placebo T1
SA384166Nieman_C_49Urine Study Placebo T1
SA384167Nieman_C_94Urine Study Placebo T1
SA384168Nieman_C_23Urine Study Placebo T1
SA384169Nieman_C_55Urine Study Placebo T1
SA384170Nieman_C_11Urine Study Placebo T1
SA384171Nieman_C_60Urine Study Placebo T1
SA384172Nieman_C_7Urine Study Placebo T1
SA384173Nieman_C_95Urine Study Placebo T2
SA384174Nieman_C_91Urine Study Placebo T2
SA384175Nieman_C_85Urine Study Placebo T2
SA384176Nieman_C_97Urine Study Placebo T2
SA384177Nieman_C_4Urine Study Placebo T2
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 129

Collection:

Collection ID:CO003614
Collection Summary:Participants included 25 healthy male and female non-elite cyclists that met the inclusion criteria including 18 to 55 years of age, and capable of cycling 2.25 h in a laboratory setting at 70% maximal oxygen consumption rate (VO2max). A randomized, placebo-controlled, double-blind, crossover design was used with two 4-week supplementation periods and a 2-week washout period. Supplementation periods were followed by an intensive 2.25-h cycling bout. Six blood samples were collected before and after supplementation (overnight fasted state), and at 0h-, 1.5h-, 3h-, and 24h-post-exercise. Stool and urine samples were collected pre- and post-supplementation.
Sample Type:Urine
Storage Conditions:-80℃

Treatment:

Treatment ID:TR003630
Treatment Summary:N/A

Sample Preparation:

Sampleprep ID:SP003628
Sampleprep Summary:Study samples were shipped from Human Performance Laboratory (Nieman Laboratory) at Appalachian State University to the UNC NRI Metabolomics and Exposome Laboratory (MEL) on dry ice. The MEL thawed and transferred 50 µL of the study samples to a new set of tubes and used them for the analysis. An additional 10 µL was taken from the original study sample and transferred to another tube to make the total study pool for this project, and then distributed with 50 µL per aliquot, used as quality control study pools (QC study pools) throughout the whole analysis. All sample aliquots (50 µL each) and QC study pools (50 µL each) were stored at -80° C until the day of sample preparation. Aliquots (50 uL) of NIST urine (SRM 3672) reference material (50 µL each) were used as external urine reference. LC-MS grade water (50 µL) was used as blanks. All samples were thawed at 4°C overnight before the preparation. Samples, including study samples, study pool samples, NIST reference urine, and blanks were mixed with 400 µL methanol containing 500 ng/mL tryptophan-d5 as internal standard and vortexed by a multiple tube vortex mixer for 2 min at 5000 rpm at room temperature. All samples were centrifuged at 16,000 rcf for 10 min at 4°C. The supernatant (350 µL) was transferred into a pre-labeled 2.0 mL Lo-bind Eppendorf tube, dried by a SpeedVac overnight, and stored at -80° C. For immediate analysis, 100 µL of water-methanol solution (95:5, v/v) was used to reconstitute the dried extracts. Samples were thoroughly mixed on a multiple tube vortex mixer for 10 min at 5000 rpm at room temperature and then centrifuged at 4°C for 10 min at 16,000 rcf. The supernatant was transferred to pre-labeled autosampler vials for data acquisition by LC-MS.
Processing Storage Conditions:4℃
Extraction Method:Vortex with methanol containing 500ng/ml tryptophan-d5 as internal standard
Extract Storage:-80℃
Sample Resuspension:Water-Methanol (95:5, v/v)

Chromatography:

Chromatography ID:CH004352
Chromatography Summary:Reversed phase
Instrument Name:Thermo Vanquish
Column Name:Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um)
Column Pressure:6000-10000 psi
Column Temperature:50 ℃
Flow Gradient:Time(min) Flow Rate(mL/min) %A %B Curve 1. 0 0.4 99.0 1.0 5 2. 1.00 0.4 99.0 1.0 5 3. 16.00 0.4 1.0 99.0 5 4. 19.00 0.4 1.0 99.0 5 5. 19.50 0.4 99.0 1.0 5 6. 22.00 0.4 99.0 1.0 5
Flow Rate:0.4 mL/min
Injection Temperature:8 ℃
Internal Standard:Tryptophan-d5
Solvent A:100% water; 0.1% formic acid
Solvent B:100% methanol; 0.1% formic acid
Analytical Time:22 min
Weak Wash Solvent Name:10% methanol/90% water; 0.1% formic acid
Strong Wash Solvent Name:75% 2-Propanol/25% Water; 0.1% formic acid
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN005733
Analysis Type:MS
Acquisition Date:6/2/2023-6/16/2023
Software Version:Xcalibur 4.1.31.9
Detector Type:Orbitrap
Data Format:Profile
Chromatography ID:CH004352
Has Mz:1
Has Rt:1
Rt Units:Minutes
Results File:ST003493_AN005733_Results.txt
Units:Normalized Intensity
  logo